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Background: Gene expression microarray has been the primary biomarker platform ubiquitously applied in
biomedical research, resulting in enormous data, predictive models, and biomarkers accrued. Recently, RNA-seq has
looked likely to replace microarrays, but there will be a period where both technologies co-exist. This raises two
important questions: Can microarray-based models and biomarkers be directly applied to RNA-seq data? Can future
RNA-seq-based predictive models and biomarkers be applied to microarray data to leverage past investment?
Results: We systematically evaluated the transferability of predictive models and signature genes between
microarray and RNA-seq using two large clinical data sets. The complexity of cross-platform sequence correspondence
was considered in the analysis and examined using three human and two rat data sets, and three levels of mapping
complexity were revealed. Three algorithms representing different modeling complexity were applied to the three
levels of mappings for each of the eight binary endpoints and Cox regression was used to model survival times with
expression data. In total, 240,096 predictive models were examined.
Conclusions: Signature genes of predictive models are reciprocally transferable between microarray and RNA-seq data
for model development, and microarray-based models can accurately predict RNA-seq-profiled samples; while
RNA-seq-based models are less accurate in predicting microarray-profiled samples and are affected both by the
choice of modeling algorithm and the gene mapping complexity. The results suggest continued usefulness of legacy
microarray data and established microarray biomarkers and predictive models in the forthcoming RNA-seq era.Background
Microarray-based gene expression profiling represents a
mature, high-throughput, transcriptomic analysis approach
that has been extensively applied in biomedical and clinical
research as the major biomarker tool for almost two de-
cades. An important outcome is a number of large-scale
microarray data sets for public reference, for example,
the Connectivity Map (also known as CMAP) database
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unless otherwise stated.DrugMatrix [4], and the Japanese Toxicogenomics
Database (TG-GATEs) [5]. Meanwhile, a large number
of microarray-based gene signatures and biomarkers
[6-9] and gene expression profile-based predictive models
[10-12] have also been established for human disease sub-
type classification, disease diagnosis and prognosis, and
therapeutic treatment selection.
During more recent years, next-generation sequencing
technologies (NGS) have emerged as a powerful alterna-
tive to microarrays, particularly for whole transcriptome
analysis with RNA-Seq [13-15]. Besides providing accurate
measurement of gene expression levels, RNA-Seq is add-
itionally promising because of its capability to discover
splicing junctions, novel transcripts, alternative splicing
variants, and un-annotated genes. The unprecedented dis-
covery features as well as a sustained cost decrease areis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Seq for clinical biomarker development. The advent of
evermore economical NGS has led many companies and
institutions that have heavily invested in microarrays to
ask whether they need to repeat their sample profiling
with NGS. Such a costly undertaking could be averted de-
pending on the extent to which predictive models and as-
sociated signature genes developed from microarrays can
be directly transferred to RNA-Seq data. Given the fact
that the cost for RNA-Seq is rapidly decreasing, the same
transferability question could be raised again in the future
on how predictive models and associated signature genes
based on RNA-Seq can be applied back to the legacy
microarray data to leverage the existing data and know-
ledge. Moreover, the analysis of the current Gene Expres-
sion Omnibus (GEO) database revealed several important
observations (Additional file 1: Figure S1). First, by only
examining the number of data added to GEO from both
technologies in 2014, much larger number of array data
(54,206) was deposited compared to RNA-Seq (9,082).
Second, justifying the year as a starting point for which
both array data (2001) and RNA-Seq data (2006) were
? seen? by GEO, the growth rate for RNA-Seq was slower
compared to microarrays in the following 5 to 7 years.
Third, projecting the data growth by fitting the existing
data with the polynomial and power equations for micro-
array and RNA-Seq, respectively, it seems that RNA-Seq
will reach 1 million mark in 2021 (the current number of
arrays in GEO) and surpass microarrays in 2028. The ana-
lysis indicated a long period of co-existence of both tech-
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EFS: Event-free survival; FAV: Unfavorable/Favorable (class label for extreme diseasecould last many years), rendering these aforementioned
questions even more important.
As a part of the FDA-led community wide Sequencing
Quality Control (SEQC) project [16], we broadly assessed
the transferability of predictive models and signature
genes between microarray and RNA-Seq data using two
large clinical data sets: the neuroblastoma (NB) data
(Zhang W, Shi L, Hertwig F, Thierry-Mieg J, Zhang W,
Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V,
Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin
S, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang
W, Wang M, Yu Y, Ai J, Albanese D, Amur S, Asgharzadeh
S, Avigad S, Bao W, et al. Comparison of RNA-seq and
microarray-based models for clinical endpoint predic-
tion; submitted) having 498 NB samples with six binary
clinical endpoints and four continuous survival times and
the acute myeloid leukemia (AML) data [17] containing
175 AML samples with two binary clinical endpoints and
two continuous survival times (Table 1). ? Signature genes?
of a predictive model are defined as the set of RNA-Seq
genes or microarray probes/probe sets used by the pre-
dictive model. The samples in both clinical data sets
were independently profiled with microarray and Illumina
RNA-Seq technologies. To ensure a rigorous comparison,
we first investigated the cross-platform sequence corres-
pondence between microarray probes/probe sets and
RNA-Seq genes for three human and two rat data sets
having both microarray and RNA-Seq data available for
the same samples. Consequently, microarray probes/probe
sets and RNA-Seq genes were cross mapped and stratified
into four mapping groups A, B, C, and D in accordanceNB samples and the 175 AML samples
Training set Validation set
Samples(n) 1 0 Samples(n) 1 0
249 89 160 249 94 155
249 51 198 249 54 195
249 103 146 249 108 141
able) 136 45 91 136 46 90
86 55 31 90 65 25
86 43 43 90 49 41
89 43 46 86 39 47







course); HR: High-risk patients; OS: Overall survival.
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Table 2. Three predictive modeling algorithms repre-
senting different modeling complexity, k-nearest neigh-
bors (k-NN), nearest shrunken centroids (NSC) [18], and
support vector machine (SVM) were applied to each of
the three mapping groups A, B, and C, and for each of the
eight binary clinical endpoints and Cox proportional
hazards survival analysis [19] was applied to the six con-
tinuous endpoints to model survival times with gene ex-
pression data (Table 1). Our analyses indicate that the
signature genes of models between microarray and
RNA-Seq data are reciprocally transferable for model
development, regardless of the degree of clinical end-
point prediction difficulty and the cross-platform gene
mapping complexity. More importantly, the models de-
veloped from microarray data could be directly used to
accurately predict RNA-Seq-profiled samples, as long as
microarray and RNA-Seq data were properly trans-
formed. Conversely, the models derived from RNA-Seq
data could be directly used to predict microarray-profiled
samples, but with more difficulty and lower accuracy.
Results
Examining the reciprocal transferability of predictive
models and signature genes between microarray and
RNA-Seq data requires understanding the sequence cor-
respondence in gene mappings between the two plat-
forms. Consequently, we first performed cross-platform
mappings of microarray probes or probe sets to RNA-
Seq genes and explored the consistency of gene expres-
sion measurements between microarray and RNA-Seq
data using two rat and three human data sets having
both microarray and RNA-Seq data. The two rat data
sets were from the NCTR rat toxicogenomics study
[20,21] and the FDA SEquencing Quality Control (SEQC)
rat toxicogenomics study [22]; and the three human
data sets were from the FDA SEQC main study [16],
MicroArray Quality Control (MAQC) phase I main
study [23], the SEQC neuroblastoma (NB) study, and The
Cancer Genome Atlas (TCGA) acute myeloid leukemia
(AML) study [17]. Subsequently, only the FDA SEQC NB
and TCGA AML data sets were used for a quantitative as-
sessment of the cross-platform transferability conductedTable 2 Gene mapping groups with different sequence corres
Group Microarray probes/probe sets R
A Each probe set can be exclusive mapped to one RNA-Seq gene.
It is identical to RNA-Seq A set
E
se
B Each probe set can be mapped to one RNA-Seq gene, but the





C Each probe set can be mapped to multiple RNA-Seq genes E
D Probe sets cannot be mapped (unique probe set) G(1) at the signature gene level (Figure 1a) and (2) at the
model level [24] (Figure 1b) for both binary endpoint pre-
diction and Cox survival regression analysis. We first ap-
plied the whole transferability assessment processes to the
FDA SEQC NB data set and then validated the findings
using the TCGA AML data set. Since gene mappings be-
tween microarray and RNA-Seq are not in one-to-one
correspondence, we independently performed the signa-
ture level assessment process (Figure 1a) on the three
groups of gene mappings (A, B, and C in Table 2) for each
of the eight binary predefined clinical endpoints using three
modeling algorithms and for each of the six continuous
survival times using Cox survival analysis. In total, we
carried out 180 signature level assessment processes
(three gene mapping groups by eight endpoints by three
algorithms by two transfer directions for binary end-
point prediction and three gene mappings by six con-
tinuous survival times by two transfer directions for
Cox modeling) and thereby generated 144,072 predict-
ive models (500 trained models plus 500 corresponding
transferred models per process for binary endpoint pre-
diction and two models per process for Cox modeling).
For model level assessment, the process (Figure 1b) was
conducted on both original log2 intensity/counts data
and per sample z-scored data; and group C mappings
were excluded from modeling since their ambiguous map-
ping relationships were not suitable for cross-platform
prediction. Thus, we conducted 216 model level assess-
ment processes (two gene mapping groups by eight end-
points by three algorithms by two transfer directions by
two forms of data for binary endpoint prediction and two
gene mappings by six continuous survival times by two
transfer directions for Cox modeling) and thereby gener-
ated 96,024 predictive models (500 trained models per
process for binary endpoint prediction and one model per
process for Cox modeling). Figure 2a,b, and c show the
summary of the assessment results for each scenario.
Cross-platform gene mapping complexity and consistency
of gene expression measurements between microarray
and RNA-Seq
Gene mapping is an essential step to assess the transfer-
ability of gene expression-based predictive modelspondence complexity
NA-Seq genes Concordance
ach gene can be exclusively mapped to one array probe
t. It is identical to array A set
High
ach gene can be mapped to one array probe set, but
e probe set can mapped to multiple genes. It is a
bset of array C set
Low
ach gene can be mapped to multiple array probe sets Lowest
enes cannot be mapped (unique genes) Unique
features
Figure 1 Flowcharts for evaluating the cross-platform transferability of signature genes and predictive models. Two analysis procedures
were applied to evaluate the transferability of signature genes (a) and predictive models (b). In (a), microarray training data are used to develop
500 trained models through (c) to predict the microarray validation samples. The signature genes of each model are then used with the RNA-Seq
training data to build an untrained RNA-Seq model using through (d) to predict the RNA-Seq validation samples. The performance of microarray
models is finally compared to that of RNA-Seq models. The transferability of signature genes from RNA-Seq back to microarray data can conversely be
calculated. While in (b), both microarray and RNA-Seq data were z-scored prior to model development. Then microarray training data are used to
develop 500 trained models to predict both microarray and RNA-Seq validation samples. The performance of models in predicting microarray data is
compared to that in predicting RNA-Seq data. From RNA-Seq back to microarray is conversely examined. A trained model is developed through (c).
Briefly, training samples are randomly split in a 70/30 ratio. For each split, a series of models are developed using the 70% of training samples to predict
the remaining 30%. The models are developed as follows: (1) all genes are first filtered with t-test P <0.05 and then ranked by fold change (FC); (2) a
sequential forward feature selection by a step of two and parameter selection strategy is then used to build a number of models to predict the
remaining samples. Finally, the signature genes and parameters of the best model are used with all training samples to build a trained model. An
untrained model is built using all training samples from one platform but with the signature genes and parameters of a model trained from the other
platform (d).
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mapping is complicated by disparity between array an-
notations and RNA-Seq gene models. Moreover, given
the complexity of human transcriptomes and the lack of
complete genome functional annotation [25], geneannotations from different sources may be inconsistent.
Even within a given source, gene annotations undergo
constant change. The inconsistency complicates array
annotation and causes variation in RNA-Seq analysis as
well. We used diverse data sets from microarray and
Figure 2 Summary of the transferability of signature genes and predictive models between microarray and RNA-Seq data. The test
results whether the parameters and signature genes of a model developed from one platform (microarray or RNA-Seq) can be used to build a
model using data generated with the other platform (RNA-Seq or microarray) are shown in (a) for the three gene mappings A, B, and C separately;
while the results whether a predictive model developed from one platform can be directly used to accurately predict the samples profiled with
the other platform for gene mappings A and B are summarized for per sample z-scored data and without per sample z-scored data in (b) and
(c), respectively. Green and red arrows indicate the good and bad transferability from one platform to the other, respectively.
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arrays, Agilent human arrays, and Illumina HiSeq 2000,
HiScanSQ, and GA-II to characterize and categorize the
complexity of cross-platform gene mappings and the
consistency of gene expression measurements.
We first mapped Affymetrix Rat_230_2 arrays to Illu-
mina GA II RNA-Seq using the method depicted in Fig-
ure 3a (see also Methods and Materials). Data were from
an NCTR rat toxicogenomics study [20] in which eight
rat kidney samples were separately profiled with
Rat_230_2 arrays and GA-II RNA-Seq. After mapping
array probe sets to RNA-Seq genes, the 31,099 array
probe sets were split into four groups A, B, C, and D
(defined in Table 2) having 8,350, 7,736, 2,121, and 12,892
probe sets, respectively. Group A contains probe sets that
can be exclusively mapped to one RNA-Seq gene; group Bincludes probe sets that can be uniquely mapped to one
RNA-Seq gene, but the RNA-Seq gene can be mapped to
multiple array probe sets; group C consists of probe sets
that can be mapped to multiple RNA-Seq genes; and
group D are microarray unique probe sets that cannot be
mapped to any RNA-Seq genes. The gene expression
levels in groups A, B, and C detected with microarrays
were compared to those detected with RNA-Seq for one
of the eight RNA samples (Figure 3b,c, and d). As can be
seen from the scatter plots, gene expression measure-
ments for genes in group A are much more consistent
than those in groups B and C. The average Spearman ? s
correlation coefficients between microarray and RNA-
Seq measurements for groups A, B, and C are 0.87, 0.60,
and 0.54, respectively. The same trend was observed in
the mapping results from Affymetrix HG-U133_Plus_2
Figure 3 The strategy for cross-platform gene mapping and the consistency of cross-platform gene expression measurements. The
microarray probes/probe sets are mapped to RNA-Seq genes in one of two ways: public gene ID mapping or genome location mapping (a). Using
the gene ID mapping approach requires that one of the following public gene IDs be available: gene symbol, RefSeq transcript ID, Ensembl gene ID,
or Entrez gene ID. Using the genome location mapping requires an RNA-Seq gene annotation file in either the Gene Transfer Format (GTF) or the
General Feature Format (GFF). The process produces separate mapping lists for microarrays and RNA-Seq. Each of them consists of A, B, C, and D
groups. Group A for microarrays corresponds to the group A in RNA-Seq. The microarray group B is a subset of RNA-Seq group C, and vice versa. The
D group for microarrays and for RNA-Seq contain genes and probes/probe sets that cannot be mapped between the two platforms. The intensities of
Affymetrix microarray probe sets in mapping groups A, B, and C are separately compared to those of RNA-Seq gene counts in panels (b), (c), and (d) for one of
the eight RNA samples in the NCTR toxicogenomics data set. The microarray data are from Rat_230_2 arrays normalized with the MAS5 algorithm, and the
RNA-Seq reads are from the Illumina GA II platform with the single-end 36 base pairs RNA-Seq protocol and gene counts from the P2 pipeline (Novoalign with
RefSeq rat gene models). The mappings from microarray probe sets to RNA-Seq genes are based on the genome location mapping approach.
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file 2: Figure S2 and Additional file 3: Figure S3) and
from Agilent human arrays to Illumina HiSeq 2000
(Table 3 and Additional file 4: Figure S4).
We then mapped Affymetrix Rat_230_2 arrays to six
RNA-Seq gene sets generated from the same raw data of
62 rat liver samples using different bioinformatics
pipelines and references, representing a diversity of ap-
proaches popularly used in RNA-Seq data analysis [22].
Array probe sets were mapped to each of the six gene
sets using either the gene ID or genome location mapping
approaches (Table 4). The percentage of array probe sets in
groups A, B, C, and D for the six gene sets varied with the
choice of analysis pipelines and references (Figure 4). A high
percentage of array probe sets (group D) in the range of
32% to 48% could not be mapped to any RNA-Seq genes,
though this group of array probe sets provides additional
information to RNA-Seq analysis. The correlationpattern exhibited by groups A, B, and C (Table 3 and
Additional file 5: Figure S5) is similar to that observed
from the previous four analyses. The average Spearman? s
correlation coefficients between microarray and RNA-Seq
measurements from the 62 rat liver samples for groups A,
B, and C are 0.88, 0.65, and 0.55, respectively (Table 3).
The results indicate that, although the numbers of genes
in the four groups from the six mapping results are quite
different (in the range of 5,653 to 8,356, 7,543 to 12,228,
91 to 3,189, and 10,029 to 14,799 for groups A, B, C,
and D, respectively), the genes in group A consistently
show the highest cross-platform concordance followed
by groups B and C. The inconsistency and ambiguity
between microarray and RNA-Seq gene models are ap-
parent. In the subsequent analysis, we investigated the
cross-platform transferability of signature genes and
models separately and explored the potential impact of
such gene mapping inconsistency and ambiguity.
Table 3 Spearman ? s correlation coefficients of gene expression levels detected with microarray and RNA-Seq
Data set Microarray RNA-Seq platform
and pipeline
Gene group Probes/probe sets (n) Spearman? s correlation
coefficient
NCTR rat TGx Affymetrix P2 A 8,350 0.87 ? 0.02
Rat_230_2 B 7,736 0.60 ? 0.04
C 2,121 0.54 ? 0.04
SEQC main Affymetrix P2 A 6,355 0.84 ? 0.01
HG_U133_Plus 2 B 27,166 0.53 ? 0.02
C 7,636 0.33 ? 0.02
SEQC NB Agilent P2 A 10,042 0.73 ? 0.03
customized 4 ? 44 k B 13,401 056 ? 0.04
C 2,543 0.49 ? 0.04
SEQC rat TGx Affymetrix P1 A 7,829 0.88 ? 0.01
Rat_230_2 B 8,376 0.63 ? 0.01
C 95 0.64 ? 0.03
P2 A 8,386 0.87 ? 0.01
B 8,035 0.68 ? 0.01
C 3,149 0.58 ? 0.01
P3 A 8,201 0.89 ? 0.01
B 8,142 0.69 ? 0.01
C 702 0.73 ? 0.01
P4 A 8,080 0.88 ? 0.01
B 8,160 0.67 ? 0.01
C 91 0.64 ? 0.04
P5 A 8,197 0.85 ? 0.01
B 7,543 0.66 ? 0.01
C 1,750 0.32 ? 0.01
P6 A 5,663 0.90 ? 0.01
B 12,228 0.59 ? 0.01
C 3,189 0.38 ? 0.02
TCCGA ALM Affymetrix Bwa + In A 7,448 0.82 ? 0.04
HG_U133_Plus 2 House B 31,313 0.66 ? 0.04
Program C 551 0.57 ? 0.04
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to RNA-Seq data for model development
To assess the transferability of signature genes from
microarray to RNA-Seq data, we first applied the signa-
ture level assessment process (Figure 1a, red line) to the
FDA SEQC NB data set. The data set was derived from
the 498 NB samples that were independently profiled
with Agilent microarrays and Illumina HiSeq 2000. Six
binary clinically relevant endpoints of varying degrees
of clinical complexity and prediction difficulty were
included in the SEQC NB study. As shown in Table 1,
A_EFS_All represents event-free or not at a certain time
point, where event means the occurrence of progression,
relapse or death; B_OS_All denotes whether patients died
from disease or not at a specific time point; C_SEX_All isthe patients? sex; D_FAV_All represents event-free without
chemotherapy for at least 1,000 days post diagnosis or
died from disease despite chemotherapy; E_EFS_HR and
F_OS_HR are similar to A_EFS_All and B_OS_All, re-
spectively, but only for the patients with stage four dis-
ease or with MYCN-amplified tumors. For each of the
six binary endpoints, a set of training samples and a set
of validation samples were predefined in the SEQC NB
study.
We first mapped Agilent array probes to RNA-Seq
genes and then sorted them into groups A, B, C, and D
in accordance with gene mapping complexity. As indi-
cated above, the probes in groups A, B, and C exhibited
different degrees of consistency in gene expression mea-
surements between microarray and RNA-Seq (Table 3
Table 4 Bioinformatics pipelines and gene models used for RNA-Seq data analysis
Data set Pipeline Aligner Counting and
normalization
Reference genome Gene annotation Mapping
approach
SEQC NB P2 Novo align
v2.08.01





Global scaling to RPM UCSC rn4 Rat RefSeq RNA v52 Location
mapping
SEQC main [16] P2 Novo align
v1.7.01









Global scaling to RPM UCSC rn4 Rat RefSeq RNA v52 ID mapping
P3 Bwa 0.5.9-r16 Samtools 0.1.13 Rat RefSeq RNA v50 ID mapping
P4 To phat HTSeq-count 0.53p3 UCSC rn4 Rat RefSeq RNA v50 ID mapping
P5 Bowtie v0.12.7 RSEM v1.1.18 Ensemble rat genome
66
Ensemble genes build 66 Location
mapping




TCGA AML [17] Bwa 0.5.7 In-house program hg18 + exon junction Ensembl v59 ID mapping
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used the probes in groups A, B, and C as features to de-
velop 500 trained k-nearest neighbors (k-NN) models
using microarray training samples for each individual
binary clinical endpoint to predict the microarray valid-
ation samples. The 500 microarray models were trainedFigure 4 The percentages of probe sets in mapping groups A, B, C, a
groups A, B, C, and D for the six RNA-Seq gene sets are shown in stacked b
62 RNA-Seq assays from the same set of 62 rat liver RNA samples. The micr
data were analyzed by six independent data analysis teams with a variety o
gene models), P3 (Bwa + RefSeq RNAs), P4 (Tophat + HTSeq with RefSeq ge
(Tophat + cufflinks de novo assembly). The Affymetrix probe sets (31,099 in
mappings to P1, P2, P3, and P4 gene sets are based on the gene ID mapp
the genome location mapping.using the stratified random sample splitting approach
(Figure 1c). For each of the 500 models, the parameter
k and signature genes were then used with all RNA-
Seq training data for those genes to build an untrained
RNA-Seq k-NN model (Figure 1d) to predict the RNA-Seq
validation samples. Finally, the prediction performance of thend D. The percentages of Affymetrix probe sets in four mapping
ar charts. The data set comprises 62 Affymetrix Rat_230_2 arrays and
oarray data were normalized with MAS5, and the same RNA-Seq raw
f analysis pipelines, that is, P1 (NCBI Magic), P2 (Novoalign with RefSeq
ne models), P5 (Bowtie + RSEM with Ensembl gene models), and P6
total) were separately mapped to the six RNA-Seq gene sets. The
ing approach, while mappings to P5 and P6 gene sets are based on
Table 5 Performance metrics for the assessment of cross-platform transferability of signature genes of k-NN models
based on the SEQC NB data
Direction Endpoint Gene
set
Microarray models Is predict microarray
validation samples
RNA-Seq models predict RNA-Seq validation
samples
T-index
Accuracy AUC Accuracy AUC
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
From microarray
to RNA-Seq
A* A 0.732 0.667-0.775 0.708 0.645-0.758 0.728 0.653-0.771 0.696 0.627-0.746 0.729
B 0.721 0.655-0.759 0.691 0.631-0.733 0.714 0.647-0.759 0.678 0.614-0.726 0.716
C 0.696 0.639-0.735 0.664 0.609-0.704 0.702 0.654-0.747 0.670 0.631-0.713 0.700
B* A 0.780 0.747-0.811 0.667 0.615-0.72 0.787 0.755-0.815 0.648 0.601-0.694 0.786
B 0.777 0.743-0.807 0.643 0.585-0.704 0.794 0.755-0.827 0.659 0.580-0.725 0.791
C 0.789 0.739-0.827 0.678 0.613-0.732 0.788 0.747-0.819 0.660 0.620-0.711 0.788
C* A 0.978 0.971-0.992 0.978 0.971-0.992 0.992 0.992-0.992 0.992 0.992-0.992 0.992
B 0.989 0.983-0.992 0.989 0.984-0.992 0.989 0.983-0.992 0.989 0.984-0.992 0.989
C 0.931 0.900-0.954 0.935 0.905-0.958 0.988 0.975-0.992 0.988 0.976-0.992 0.984
D* A 0.934 0.882-0.971 0.920 0.863-0.962 0.921 0.882-0956 0.895 0.848-0.940 0.921
B 0.947 0.824-0.978 0.938 0.798-0.973 0.933 0.772-0.978 0.915 0.737-0.967 0.934
C 0.915 0.838-0.956 0.911 0.841-0.961 0.921 0.853-0.963 0.914 0.840-0.956 0.920
E* A 0.624 0.533-0.700 0.534 0.463-0.615 0.606 0.522-0.689 0.537 0.460-0.617 0.612
B 0.562 0.478-0.623 0.507 0.417-0.588 0.569 0.500-0.633 0.519 0.443-0.595 0.566
C 0.607 0.511-0.689 0.513 0.437-0.603 0.599 0.511-0.689 0.515 0.438-0.603 0.602
F* A 0.513 0.444-0.589 0.513 0.446-0.585 0.510 0.433-0.589 0.510 0.426-0.589 0.511
B 0.507 0.456-0.567 0.511 0.452-0.572 0.490 0.422-0.556 0.498 0.431-0.562 0.498
C 0.532 0.456-0.611 0.534 0.460-0.609 0.527 0.444-0.611 0.531 0.448-0.611 0.529
From RNA-Seq
to microarray
A* A 0.701 0.614-0.759 0.669 0.590-0.732 0.709 0.643-0.759 0.671 0.603-0.727 0.703
B 0.680 0.584-0.741 0.644 0.543-0.708 0.693 0.604-0.747 0.651 0.568-0.710 0.684
C 0.719 0.647-0.767 0.691 0.618-0.748 0.730 0.648-0.771 0.698 0.621-0.743 0.722
B* A 0.775 0.715-0.819 0.662 0.576-0.737 0.775 0.733-0.811 0.640 0.579-0.696 0.775
B 0.777 0.715-0.819 0.639 0.552-0.713 0.785 0.735-0.825 0.640 0.566-0.718 0.778
C 0.792 0.749-0.823 0.681 0.621-0.757 0.790 0.753-0.819 0.659 0.606-0.728 0.791
C* A 0.971 0.967-0.992 0.972 0.969-0.992 0.984 0.983-0.992 0.985 0.984-0.992 0.971
B 0.939 0.900-0.950 0.943 0.901-0.954 0.990 0.988-0.992 0.990 0.988-0.992 0.939
C 0.987 0.975-0.992 0.987 0.975-0.992 0.987 0.971-0.992 0.987 0.972-0.992 0.987
D* A 0.914 0.809-0.971 0.899 0.792-0.957 0.927 0.868-0.963 0.910 0.841-0.951 0.915
B 0.918 0.838-0.963 0.907 0.825-0.962 0.928 0.860-0.971 0.908 0.836-0.957 0.918
C 0.937 0.875-0.978 0.923 0.853-0.973 0.933 0.882-0.971 0.913 0.882-0.962 0.937
E* A 0.598 0.456-0.689 0.506 0.414-0.606 0.598 0.444-0.700 0.522 0.400-0.630 0.598
B 0612 0.511-0.700 0.513 0.432-0.602 0.588 0.489-0.678 0.510 0.415-0.613 0.603
C 0.582 0.478-0.667 0.512 0.412-0.633 0.596 0.500-0.689 0.522 0.432-0.615 0.587
F* A 0.507 0.433-0.600 0.502 0.421-0.590 0.498 0.400-0.600 0.496 0.406-0.597 0.503
B 0.500 0.411-0.595 0.503 0.414-0.596 0.493 0.400-0.589 0.503 0.411-0.601 0.496
C 0.523 0.456-0.600 0.527 0.452-0.602 0.498 0.405-0.578 0.505 0.411-0.59 0.511
A*: A_EFS_All; B*: B_OS_All; C*: C_SEX_All; D*: D_FAV_All; E*: E_EFS_HR; F*: F_OS_HR; AUC: Area under ROC curve; CI: Confidence interval; 95% CI was calculated
from the bootstrap estimation. The upper-right and lower-left regions are for the untrained models built using cross-platform transferred signature genes, while
the upper-left and lower-right regions are for the models originally trained.
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500 corresponding untrained RNA-Seq models to assess
the transferability of signature genes from microarray
to RNA-Seq. The performance of each model in predict-
ing validation samples was assessed with accuracy and the
area under the receiver-operating characteristic curve
(AUC) (Table 5). The average prediction accuracies of the
microarray models for each mapping group and each end-
point were compared to those of the transferred RNA-
Seq models (Figure 5a). All 18 (three mapping groups
by six endpoints) average prediction accuracy pairs
closely locate to the diagonal of the square indicating the
comparable prediction ability of the transferred RNA-Seq
models and the original microarray models (paired t-test P
is 0.718). The comparability is the same in terms of AUC.Figure 5 A performance comparison of k-nearest neighbors (k-NN)
comparison is based on the SEQC NB data set. For each of the six binar
set of 500 k-NN models were developed from microarray training data and u
signature genes of each of the 500 microarray models were then used
RNA-Seq model to predict RNA-Seq validation samples. Finally, the average p
those of the 500 corresponding RNA-Seq models (a), with the per sam
in (b). The transferability of the signature genes from RNA-Seq back to microa
RNA-Seq data were used to predict RNA-Seq validation samples. Then the
used with all microarray training data for those genes to build a microarray m
the 500 RNA-Seq models are compared to those of the 500 corresponding m
given by the Kappa statistic as shown in (d). The six symbols in each pane
orange colors denoting mapping groups A, B, and C, respectively. In pane
500 pairs of k-NNs models; and each error bar shows the 95% confidence
the bootstrap estimation.Per sample agreement beyond chance between the two
predictions from each pair of microarray and RNA-Seq
models was evaluated with Kappa statistic (Figure 5b). For
the endpoints C_SEX_ALL and D_FAV_All which are sup-
posedly easy to predict, model pairs reached perfect agree-
ment (kappa >0.8); for A_EFS_All and B_OS_All,
moderate (0.4 < kappa <0.6) to substantial agreement (0.6
< kappa <0.8) was achieved; while for the most difficult to
be predicted endpoints E_EFS_HR and F_OS_HR, fair
(0.2 < kappa <0.4) to moderate agreement was reached.
Therefore, per sample agreement is inversely correlated
to the prediction difficulty of the clinical endpoints.
The transferability of signature genes from microarray
to RNA-Seq data was assessed with T-index score [24].
As shown in Table 5, the T-index scores for transferringmodels and their corresponding transferred models. The
y clinical endpoints and each of the three mapping groups A, B, and C, a
sed to predict microarray validation samples. The k parameter and
with all RNA-Seq training data for those genes to build an untrained
rediction accuracies of the 500 microarray models are plotted against
ple agreement better than chance given by the Kappa statistic as shown
rray data was conversely calculated. The 500 k-NN models trained from
k parameter and signature genes of each RNA-Seq model were
odel to predict microarray validation samples. The average accuracies of
icroarray models (c), with the per sample agreement better than chance
l represent the six binary clinical endpoints with green, blue, and
ls (b) and (d), each symbol denotes the average Kappa statistic for the
interval (CI) for the mean Kappa statistic. Each CI was calculated with
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vary according to the clinical endpoints with only modest
variation due to the gene mapping complexity. No signifi-
cant difference was observed among three mapping
groups A, B, and C (one-way ANOVA test P is 0.996; pair-
wise paired t-test P values are 0.271, 0.571, and 0.508 for
A vs. B, A vs. C, and B vs. C, respectively). Thus, the gene
mapping complexity did not affect the transferability of
signature genes from microarray to RNA-Seq data.
To confirm these findings, we also applied nearest
shrunken centroids (NSC) and support vector machine
(SVM) modeling algorithms. Using the same comparison
workflow, the results from NSC and SVM are similar to
those from k-NN (Additional file 6: Figure S6a and S6b,
Additional file 7: Figure S7a and S7b and Additional file 8:
Table S1 and Additional file 9: Table S2). Comparing the
results from different modeling algorithms shows that, for
a specific endpoint, different modeling algorithms might
perform differently and result in different T-index scores.
For instance, the T-index scores of SVM, k-NN, and NSC
models for endpoint ?A_EFS_All? are 0.676, 0.729, and
0.734, respectively; but the performance of the predictive
models developed from microarrays and transferred from
microarrays to RNA-Seq using the same modeling algo-
rithm is consistently comparable.
Signature genes of a RNA-Seq model can be equally
transferred back to microarray data for model
development
To assess the transferability of signature genes of models
developed from RNA-Seq data to microarray data (Figure 1a,
blue line) we again used the FDA SEQC NB data, and
again applied k-NN, NSC, and SVM algorithms. We first
mapped RNA-Seq genes to Agilent array probes and sepa-
rated RNA-Seq genes into A, B, C, and D groups, as pre-
sented in Table 2. For each algorithm and each group of
A, B, and C genes, we used RNA-Seq training samples to
develop 500 trained models through the process shown in
Figure 1c to predict the RNA-Seq validation samples.
Then the parameters and signature genes of each model
were used with all microarray training samples for those
genes to build an untrained microarray model to subse-
quently predict the microarray validation samples. The
prediction performance of the trained RNA-Seq models
was compared to that of the corresponding transferred
microarray models using the same metrics as above
(Table 5, Figure 5c and d, Additional file 6: Figure S6c,
Figure S6d, Additional file 7: Figure S7c, and S7d, and
Additional file 8: Table S1 and Additional file 9: Table S2).
The results show that the performance of transferred un-
trained microarray models is comparable to that of ori-
ginal trained RNA-Seq models. There is no significant
difference between the accuracies of the untrained micro-
array models and the trained RNA-Seq models (paired t-test P values are 0.356, 0.058, and 0.158 for k-NN, NSC,
and SVM, respectively). Thus, signature genes identified
from RNA-Seq can also be directly transferred back to
microarray data for model development without signifi-
cant loss of predictive accuracy. Again, the cross-platform
gene mapping complexity did not affect the transferability
of RNA-Seq signature genes back to microarray data.
Microarray models can accurately predict samples
profiled with RNA-Seq
To test whether the predictive models trained from micro-
array data can directly predict RNA-Seq-profiled samples,
we conducted the model level evaluation process
(Figure 1b, red line) on gene mappings A and B separately
(the genes in group C were excluded from this analysis
due to the mapping ambiguity). Because microarray log2
intensity data are quite different from RNA-Seq log2
counts, both microarray and RNA-Seq data were z-scored
prior to the modeling process. To prevent information
leakage, z-score transformation was carried out independ-
ently for each sample and within each data set.
We trained 500 k-NN models from z-scored microarray
training data using the approach depicted in Figure 1c and
directly applied the models to predict both microarray
and RNA-Seq validation samples. The performance of the
500 models in predicting microarray samples in terms of
accuracy and AUC was compared to that in predicting
RNA-Seq samples (Figure 6a and Table 6). The average
accuracies of the models in predicting microarray data
are quite close to those in predicting RNA-Seq data
(Figure 6a), indicating that the microarray models can
directly predict RNA-Seq-profiled samples without signifi-
cant loss of prediction performance (paired t-test P is
0.093). The per sample prediction agreement assessed
with the Kappa statistic is inversely correlated to the com-
plexity of the clinical endpoints (Figure 6b). The difference
between T-index scores (Table 6) from gene mappings A
and B is not significant (paired t-test P is 0.106). The re-
sults from NSC algorithm are similar to those from k-NN
(Additional file 10: Figure S8a and S8b and Additional file 11:
Table S3).
When SVM algorithm was applied, the difference be-
tween the model performances in predicting microarray
and RNA-Seq data was quite large (Additional file 12:
Figure S9a and S9b and Additional file 13: Table S4),
particularly for endpoint C_SEX_All and gene mapping
group B (the average accuracy dropped from 0.967 to
0.824). The difference between the average accuracies in
predicting microarray and RNA-Seq data is significant
(paired t-test P is 0.008). Therefore, the transferability of
microarray models to predict RNA-Seq data is dependent
on the choice of modeling algorithms. For algorithms that
are not too sensitive to data values such as k-NN and
NSC, microarray-based models can directly be applied for
Figure 6 A performance comparison of k-nearest neighbors (k-NN) in predicting microarray and RNA-Seq validation samples. The
comparison is based on the SEQC NB data set. In the comparison, both microarray log2 intensity data and RNA-Seq log2 counts were per sample
z-scored. For each of the six binary clinical endpoints and each of the two mapping groups A and B, a set of 500 k-NN models were developed
from microarray and RNA-Seq training data independently. Each set of k-NN models were then used to predict both microarray and RNA-Seq
validation samples. The average prediction accuracies of the 500 microarray k-NN models in predicting microarray data are plotted against those
in predicting RNA-Seq data (a), with the per sample agreement better than chance evaluated with the Kappa statistic as shown in (b); while the
average accuracies of the 500 RNA-Seq k-NN models in predicting RNA-Seq data are compared to those in predicting microarray data (c), with
the per sample agreement better than chance assessed with the Kappa statistic as shown in (d). The six symbols in each panel represent the six
binary clinical endpoints with green and blue colors denoting mapping groups A and B, respectively. In panels (b) and (d), each symbol denotes
the average Kappa statistic of the 500 pairs of prediction results; and each error bar shows the 95% confidence interval (CI) for the mean Kappa
statistic. Each CI was calculated with the bootstrap estimation.
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value-sensitive algorithms such as SVM, such a direct ap-
plication is challenging.
It is more difficult to use RNA-Seq models to predict
microarray-profiled samples
We next examined the transferability of models developed
from RNA-Seq data back to predict microarray data
(Figure 1b, blue line). A set of 500 k-NN models were
trained from z-scored RNA-Seq training data and used
to predict both RNA-Seq and microarray validation
samples. As shown in Figure 6c and d and Table 6, the
accuracies of the RNA-Seq models developed from map-
ping group B in predicting microarray validation samples
for endpoints A_EFS_All, B_OS_All, C_SEX_All, and
D_FAV_All decreased considerably compared to that inpredicting RNA-Seq-profiled samples; while the models
developed from mapping group A achieved comparable
accuracies in prediction both microarray and RNA-Seq
validation samples. The similar results were observed
with NSC (Additional file 10: Figure S8c and S8d and
Additional file 11: Table S3). Thus, the transferability of
RNA-Seq models back to predict microarray data can be
substantially affected by the lack of cross-platform gene
mapping correspondence.
The performance of the RNA-Seq models dropped
dramatically in predicting microarray-profiled validation
samples when SVM was used, regardless which mapping
group of genes were used to develop RNA-Seq models
(Additional file 12: Figure S9c and S9d and Additional
file 13: Table S4). Clearly, it is more difficult and de-
graded accuracy should be expected when using the






Predicto mg microarray validation data Predicting RNA-Seq validation data T-index
Accuracy AUC Accuracy AUC
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
Models developed
from microarray
A* A 0.728 0.659-0.775 0.698 0.633-0.752 0.706 0.606-0.763 0.678 0.596-0.747 0.712
B 0.730 0.655-0.775 0.694 0.619-0.749 0.709 0.640-0.755 0.671 0.610-0.730 0.714
B* A 0.786 0.751-0.815 0.662 0.600-0.719 0.792 0.743-0.831 0.621 0.547-0.738 0.791
B 0.785 0.743-0.821 0.638 0.572-0.708 0.764 0.663-0.815 0.621 0.521-0.737 0.768
C* A 0.988 0.983-0.992 0.988 0.983-0.992 0.990 0.975-0.992 0.990 0.977-0.992 0.990
B 0.982 0.971-0.992 0.983 0.974-0.992 0.984 0.975-0.992 0.985 0.976-0.995 0.984
D* A 0.928 0.860-0.971 0.907 0.831-0.962 0.890 0.790-0.949 0.860 0.728-0.937 0.891
B 0.918 0.816-0.982 0.900 0.781-0.978 0.868 0.746-0.956 0.841 0.736-0.945 0.870
E* A 0.625 0.522-0.711 0.540 0.446-0.637 0.627 0.456-0.733 0.529 0.440-0.636 0.626
B 0.564 0.456-0.661 0.489 0.394-0.573 0.516 0.278-0.711 0.497 0.429-0.575 0.533
F* A 0.516 0.433-0.600 0.515 0.432-0.597 0.532 0.433-0.622 0.521 0.438-0.607 0.525
B 0.493 0.422-0.556 0.497 0.430-0.562 0.512 0.422-0.600 0.495 0.415-0.575 0.503
Models developed
from RNA-Seq
A* A 0.655 0.456-0.759 0.653 0.528-0.752 0.695 0.610-0.747 0.656 0.586-0.714 0.665
B 0.551 0.367-0.719 0.572 0.421-0.705 0.692 0.614-0.747 0.651 0.575-0.710 0.584
B* A 0.778 0.715-0.811 0.571 0.516-0.636 0.776 0.735-0.815 0.641 0.583-0.704 0.777
B 0.740 0.524-0.807 0.643 0.500-0.768 0.775 0.723-0.815 0.629 0.556-0.698 0.746
C* A 0.991 0.979-0.992 0.991 0.981-0.992 0.992 0.992-0.992 0.991 0.992-0.992 0.991
B 0.797 0.797-0.801 0.823 0.822-0.826 0.987 0.979-0.992 0.987 0.981-0.992 0.796
D* A 0.862 0.651-0.956 0.832 0.632-0.945 0.914 0.846-0.956 0.896 0.809-0.946 0.863
B 0.781 0.408-0.941 0.812 0.548-0.937 0.910 0.824-0.956 0.890 0.782-0.946 0.775
E* A 0.538 0.333-0.689 0.546 0.452-0.632 0.606 0.478-0.706 0.526 0.432-0.618 0.560
B 0.607 0.400-0.722 0.502 0.420-0.609 0.593 0.500-0.689 0.511 0.419-0.615 0.603
F* A 0.491 0.411-0.584 0.500 0.421-0.588 0.497 0.405-0.589 0.495 0.401-0.588 0.494
B 0538 0.456-0.600 0.505 0.440-0585 0.492 0.411-0.567 0.502 0.424-0.574 0.516
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microarray data.Data transformation is required to use the models
developed from one platform to predict samples profiled
with the other platform
We also evaluated the model level transferability (Figure 1b)
without z-score preprocessing (that is, using log2 intensity
and log2 counts data for microarray and RNA-Seq, respect-
ively). The accuracies of the models in cross-platform pre-
diction dropped dramatically for most endpoints compared
to that in predicting the samples profiled with the same
platform as used for model development (Additional file 14:
Figure S10, Additional file 15: Figure S11, and Additional
file 16: Figure S12). The results suggest that it is essential to
adequately transform both microarray and RNA-Seq data
prior to model development and cross-platform prediction.The transferability of Cox models from survival analysis
follow the similar patterns as observed from the binary
endpoint prediction analyses
The analyses above only used binary endpoints (A_EFS_All,
B_OS_All, E_EFS_HR, and F_OS_HR) for the prediction
of patient? s survival status. Because survival times were
not considered during modeling process, the analyses may
not be extrapolated to the models in which survival times
were directly modeled. To examine the transferability of
such models and associated signature genes, we applied
Cox proportional hazards survival regression to model
survival times with gene expression data for the SEQC NB
data set and compared the performance of Cox models in
terms of concordance index and P value calculated with
concordance.index and cindex.comp functions from R
package survcomp [26]. The concordance index esti-
mates the probability of concordance between predicted
and observed responses with values of 0.5, 1, and 0 for
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prediction, respectively [27].
To train a Cox ? s model, the genes in a training set were
first filtered with their median intensities (the median in-
tensity of a gene across the training samples is greater
than the median intensity of all genes across all training
samples) and P values (<0.01) calculated with the function
of concordance.index in R package survcomp [26] and
ranked according to their concordance indices. The signa-
ture genes were then selected by running a leave-one-out
cross-validation process with a one-step forward gene se-
lection approach. The final Cox model was built using all
training samples with the selected signature genes.
To assess gene level transferability, a Cox model was
first trained from a training data set from one platform
through the leave-one-out cross-validation process and
then used to predict the corresponding validation sam-
ples profiled with the same platform. The signature
genes were then used with the training data set from the
other platform to build a Cox model to predict the cor-
responding validation samples. The performance of each
Cox model was assessed with a concordance index with
a P value indicating whether the concordance index is
significantly different from 0.5. The two concordance in-
dices were finally compared with the function of cindex.
comp to test whether the first concordance index is sig-
nificantly greater than the second. As shown in Additional
file 17: Table S5, for the patient cohorts of A_EFS_All and
B_OS_All that are easier to predict, the signature genes of
Cox models can be easily transferred between the two
platforms for Cox model development. But for the high-
risk cohorts (E_EFS_HR and F_OS_HR) that are sup-
posedly more difficult to predict, the transferability is
much lower. The results are consistent with those from
the binary endpoint prediction analyses.
To examine model level transferability, we first did per-
sample z-score transformation for data and then trained a
Cox model using a training set from one platform and
then applied it to separately predict the validation samples
profiled with the two platforms. The performance of the
model in predicting both validation samples was separ-
ately measured with the concordance index and then the
two concordance indices were compared to each other
with cindex.comp. The transferability of Cox models be-
tween microarray and RNA-Seq data sets also shows a
similar pattern to those from the previous binary endpoint
prediction analyses (Additional file 18: Table S6).
Validation of the findings using The Cancer Genome Atlas
(TCGA) acute myeloid leukemia (AML) data
To validate the findings based on the NB data set, we re-
peated the same analysis processes to the TCGA AML
data set which contains 175 Affymetrix HG-U133_plus_2microarrays and Illumina HiSeq 2000 RNA-Seq assays
from the same set of AML tumor RNA samples (see
Methods and Materials) with two binary (sex and cytogen-
etic risk status) and two continuous (event-free survival
time (EFS) and overall survival time (OS)) endpoints. For
binary endpoint prediction, the three binary modeling al-
gorithms (that is, k-NN, NSC, and SVM) were separately
applied to predict patients? sex and cytogenetic risk status.
While the time to EFS and OS events of patients were
modelled with Cox proportional hazards regression as we
did for the NB data set.
At signature gene level, the untrained RNA-Seq models
built with the signature genes of trained microarray
models show comparable prediction performance ex-
cept for using the mapping group C to predict the sex of
patients (Figure 7a and b and Table 7; Additional file 19:
Figure S13a and S13b; Additional file 20: Figure S14a
and S14b). Using mapping group C, microarray-based
trained models cannot accurately predict the sex end-
point (about 50% accuracy). However, the transferred
RNA-Seq models show much better prediction capabil-
ity (about 73% accuracy). This could be explained by the
more accurate measurements of RNA-Seq. The micro-
array models built with the signature genes of trained
RNA-Seq models consistently show comparable predic-
tion performance compared to that of trained RNA-Seq
models (Figure 7c and d and Table 7, Additional file 19:
Figure S13c and S13d; Additional file 20: Figure S14c
and S14d). For EFS and OS survival time Cox regression
analysis, the original trained models and transferred
models did not show significant difference (Additional
file 21: Table S7, p4 > 0.01) except for using mapping
group C to predict EFS time in which the original trained
microarray models outperformed the transferred RNA-Seq
untrained models (p4 < 0.0018). Therefore, the signature
genes are reciprocally transferable between microarray and
RNA-Seq data.
Using the models developed from one platform to dir-
ectly predict the samples whose expression value obtained
from the other platform, the results were dependent on
several factors, that is, the selection of mapping groups,
the choice of machine learning algorithms, and/or with
or without proper data transformation (Figure 8 and
Table 8, Additional file 22: Figure S15, Additional file 23:
Figure S16, Additional file 24: Figure S17, Additional file 25:
Figure S18, Additional file 26: Figure S19). Specifically, we
found that, using microarray-based models to classify
samples with RNA-Seq based expression data, (1) k-
NN performed well except for mapping group B to
classify patients ? sex (Figure 8a and b), (2) NSC worked
well for both endpoints (sex and cytogenetic risk sta-
tus) and for both mapping groups (A and B) (Additional
file 22: Figure S15a and S15b), however (3) SVM per-
formed well only for cytogenetic risk status prediction
Figure 7 A performance comparison of k-nearest neighbors (k-NN) models and their corresponding transferred models based on the
TCGA AML data. For each of the two binary clinical endpoints and each of the three mapping groups A, B, and C, a set of 500 k-NN models
were developed from microarray training data and used to predict microarray validation samples. The signature genes of each of the 500
microarray models were then used with all RNA-Seq training data for those genes to build an untrained RNA-Seq model to predict RNA-Seq
validation samples. Finally, the average prediction accuracies of the 500 microarray models are plotted against those of the 500 corresponding
RNA-Seq models (a), with the per sample agreement better than chance evaluated with the Kappa statistic as shown in (b). The transferability of
the signature genes from RNA-Seq back to microarray data was conversely calculated. The 500 k-NN models trained from RNA-Seq data were
used to predict RNA-Seq validation samples. Then the signature genes of each RNA-Seq model were used with all microarray training data for
those genes to build an untrained k-NN model to predict microarray validation samples. The average accuracies of the 500 RNA-Seq models were
then compared to those of the 500 corresponding microarray models (c), with the per sample agreement better than chance assessed with the
Kappa statistic as shown in (d). The two symbols in each panel represent the two binary clinical endpoints with green, blue, and orange colors
denoting mapping groups A, B, and C, respectively. In panels (b) and (d), each symbol denotes the average Kappa statistic of the 500 pairs of model
predictions; and each error bar shows the 95% confidence interval (CI) for the mean Kappa statistic. Each CI was calculated with the bootstrap estimation.
No significant difference is observed between trained microarrays models and transferred RNA-Seq models (paired t-test P is 0.366) and between the
trained RNA-Seq models and the transferred microarray models (paired t-test P is 0.269).
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found that more difficult to classify samples with micro-
array data using the models developed with RNA-seq data.
For example, the performance of some models decreased
dramatically (Figure 8c and d and Table 8, Additional
file 22: Figure S15c and S15d, Additional file 23: Figure
S16c and S16d). When using the original expression data
without per sample z-score transformation, the models
developed from one platform cannot accurately predict
the samples with gene expression data obtained from the
other platform (Additional file 24: Figure S17, Additional
file 25: Figure S18 and Additional file 26: Figure S19). TheEFS and OS survival time Cox regression analysis shows
the same trend as from the SEQC NB data (Additional
file 27: Table S8).
In summary, the results from the analysis of the TCGA
AML data are consistent with those from the analysis of
the SEQC NB data.
Discussion
As a part of SEQC project, we used two large clinical
data sets to comprehensively investigate the transferability
of predictive models and associated signature genes de-
rived from microarrays to RNA-Seq data, and reciprocally
Table 7 Performance metrics for the assessment of cross-platform transferability of signature genes of predictive
models based on the TCGA AML data
Algorithm Direction Endpoint Gene
set
Microarray model RNA-Seqmodel T-index
Accuracy AUC Accuracy AUC
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
k-NN Forward Sex A 0.988 0.988-0.988 0.987 0.987-0.987 0.988 0.988-0.988 0.987 0.987-0.987 0.988
B 0.980 0.953-0.988 0.980 0.955-0.987 0.986 0.977-0.988 0.985 0.977-0.987 0.986
C 0.496 0.419-0.57 0.496 0.413-0.579 0.734 0.419-0.988 0.733 0.418-0.987 0.647
Cyto Risk A 0.945 0.907-0.988 0.895 0.805-0.993 0.947 0.872-0.988 0.905 0.794-0.993 0.947
B 0.939 0.872-0.977 0.904 0.745-0.986 0.942 0.884-0.977 0.925 0.825-0.986 0.942
C 0.919 0.848-0.965 0.884 0.767-0.964 0.907 0.872-0.953 0.854 0.776-0.948 0.908
Reverse Sex A 0.988 0.988-0.988 0.987 0.987-0.987 0.988 0.988-0.988 0.987 0.987-0.987 0.988
B 0.508 0.419-0.599 0.501 0.41-0.591 0.506 0.407-0.593 0.508 0.409-0.593 0.507
C 0.977 0.977-0.977 0.977 0.977-0.977 0.988 0.988-0.988 0.987 0.987-0.987 0.977
Cyto Risk A 0.937 0.837-0.988 0.886 0.724-0.993 0.951 0.843-0.988 0.924 0.815-0.993 0.938
B 0.856 0.744-0.919 0.758 0.59-0.888 0.848 0.767-0.907 0.748 0.589-0.893 0.855
C 0.930 0.86-0.965 0.887 0.767-0.979 0.943 0.86-0.988 0.920 0.746-0.993 0.930
NSC Forward Sex A 0.988 0.988-0.988 0.987 0.987-0.987 0.988 0.988-0.988 0.987 0.987-0.987 0.988
B 0.983 0.977-0.988 0.982 0.977-0.987 0.988 0.988-0.988 0.987 0.987-0.987 0.988
C 0.471 0.419-0.547 0.454 0.398-0.531 0.725 0.488-0.988 0.701 0.46-0.987 0.619
Cyto Risk A 0.937 0.907-0.953 0.857 0.75-0.907 0.951 0.919-0.977 0.904 0.836-0.979 0.950
B 0.892 0.837-0.93 0.860 0.707-0.933 0.891 0.872-0.907 0.873 0.801-0.919 0.891
C 0.889 0.849-0.907 0.812 0.666-0.871 0.876 0.86-0.919 0.775 0.625-0.829 0.877
Reverse Sex A 0.988 0.988-0.988 0.987 0.987-0.987 0.988 0.988-0.988 0.987 0.987-0.987 0.988
B 0.526 0.453-0.547 0.487 0.439-0.52 0.504 0.436-0.547 0.481 0.426-0.52 0.515
C 0.988 0.988-0.988 0.987 0.987-0.987 0.988 0.988-0.988 0.987 0.987-0.987 0.988
Cyto Risk A 0.926 0.872-0.977 0.828 0.656-0.986 0.929 0.907-0.977 0.913 0.846-0.986 0.927
B 0.854 0.814-0.895 0.609 0.5-0.743 0.820 0.814-0.837 0.521 0.5-0.562 0.849
C 0.907 0.884-0.925 0.907 0.863-0.954 0.886 0.872-0.942 0.852 0.794-0.964 0.905
SVM Forward Sex A 0.980 0.965-0.988 0.980 0.966-0.987 0.988 0.988-0.988 0.987 0.987-0.987 0.988
B 0.981 0.942-0.988 0.981 0.945-0.987 0.984 0.977-0.988 0.983 0.974-0.987 0.984
C 0.516 0.43-0.593 0.515 0.429-0.599 0.753 0.43-0.988 0.752 0.426-0.987 0.671
Cyto Risk A 0.939 0.895-0.988 0.879 0.774-0.993 0.957 0.895-0.988 0.919 0.774-0.993 0.956
B 0.963 0.919-0.988 0.941 0.829-0.993 0.961 0.93-0.988 0.947 0.868-0.993 0.961
C 0.919 0.884-0.953 0.901 0.832-0.964 0.920 0.86-0.965 0.888 0.736-0.979 0.920
Reverse Sex A 0.981 0.965-0.988 0.980 0.964-0.987 0.988 0.988-0.988 0.987 0.987-0.987 0.981
B 0.493 0.407-0.593 0.489 0.404-0.592 0.497 0.407-0.593 0.497 0.409-0.588 0.495
C 0.982 0.977-0.988 0.982 0.977-0.987 0.988 0.977-0.988 0.987 0.974-0.987 0.983
Cyto Risk A 0.932 0.872-0.977 0.871 0.739-0.962 0.965 0.919-0.988 0.955 0.812-0.993 0.932
B 0.845 0.756-0.919 0.778 0.608-0.895 0.869 0.779-0.942 0.787 0.583-0.925 0.847
C 0.944 0.872-0.977 0.901 0.729-962 0.964 0.907-0.988 0.944 0.846-0.993 0.944
AUC: Area under ROC curve; CI: Confidence interval; 95% CI was calculated from the bootstrap estimation.
A*: A_EFS_All; B*: B_OS_All; C*: C_SEX_All; D*: D_FAV_All; E*: E_EFS_HR; F*: F_OS_HR; AUC: Area under ROC curve; CI: Confidence interval; 95% CI was calculated
from the bootstrap estimation. The upper-right and lower-left regions are for the cross-platform prediction of the models (the training and validation samples
were profiled with different platforms), while the upper-left and lower-right regions are for the intra-platform prediction of the models (both training and validation
samples were profiled with the same platform).
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Figure 8 A performance comparison of k-nearest neighbors (k-NN) models in predicting microarray and RNA-Seq validation data based
on the TCGA AML data. In the comparison, both microarray log2 intensity and RNA-Seq log2 count were per sample z-scored. For each of the
two binary clinical endpoints and each of the two mapping groups A and B, a set of 500 k-NN models were developed from microarray and
RNA-Seq training data independently. Each set of k-NN models were then used to predict both microarray and RNA-Seq validation samples. The
average prediction accuracies of the 500 microarray-based models in prediction microarray data were plotted against those in predicting RNA-Seq
data (a), with per sample agreement better than chance assessed with the Kappa statistic as shown in (b); while the average accuracies of the 500
RNA-Seq-based models in predicting RNA-Seq data were compared to those in predicting microarray data (c), with per sample agreement
better than chance evaluated with the Kappa statistic as shown in (d). The two symbols in each panel represent the two binary clinical endpoints with
green and blue colors denoting mapping groups A and B, respectively. In panels (b) and (d), each symbol denotes the average Kappa statistic of 500
pairs of prediction results; and each error bar shows the 95% confidence interval (CI) for the mean Kappa statistic. Each CI was calculated with the
bootstrap estimation.
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is comprehensive. First, since the nature of an endpoint is
the most significant factor to determine the robustness of
a predictive model [28], our study contains eight binary
endpoints and six continuous survival times with varying
degrees of difficulty for prediction (Table 1). Second, we
observed large variation derived from array annotations
and RNA-Seq gene models when mapping genes between
microarray and RNA-Seq (Figures 3b,c,d, and 4). There-
fore, the cross-platform gene mapping complexity was
taken into consideration in the analysis. Third, realizing
the choice of modeling algorithms could affect observa-
tions; three representative classification algorithms
from simple to complicated were selected according to
their mathematical complexity. Last and most import-
antly, the investigation was conducted at both signaturegene (Figure 1a) and model levels (Figure 1b) and the
conclusions were drawn from the prediction of external
validation data sets. With this design, several important
observations were made (Figure 2a,b and c).
We observed that signature genes derived from one
platform can be directly used to build predictive models
using data generated from the other platform. We also
demonstrated that microarray-base predictive models
can directly predict RNA-Seq-profiled samples, but the
reverse process yielded less accuracy. Apparently, the ef-
fect of the cross-platform gene mapping complexity was
minimal to the transferability of signature genes between
the two platforms, but did show influence to a certain
degree at the model level. This could result from the
model ? recalibration ? step (Figure 1d) at signature level
transfer. The ? recalibration? might take care of the cross-
Table 8 The performance of models developed from one-platform in predicting microarray and RNA-Seq validation





Microarray data RNA-Seq data T-index
Accuracy AUC Accuracy AUC
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
k-NN Forward Sex A 0.988 0.988-0.988 0.987 0.987-0.987 0.977 0.977-0.977 0.977 0.977-0.977 0.977
B 0.978 0.942-0.988 0.978 0.945-0.987 0.869 0.523-0.988 0.857 0.481-0.987 0.851
Cyto Risk A 0.939 0.895-0.988 0.884 0.805-0.993 0.916 0.837-0.977 0.825 0.68-0.979 0.917
B 0.931 0.837-0.977 0.890 0.69-0.986 0.914 0.837-0.965 0.903 0.736-0.979 0.914
Reverse Sex A 0.895 0.895-0.895 0.885 0.885-0.885 0.988 0.988-0.988 0.987 0.987-0.987 0.896
B 0.512 0.419-0.593 0.503 0.426-0.58 0.508 0.407-0.593 0.509 0.409-0.6 0.510
Cyto Risk A 0.920 0.866-0.988 0.864 0.736-0.993 0.949 0.837-0.988 0.916 0.822-0.993 0.921
B 0.447 0.186-0.849 0.609 0.5-0.802 0.850 0.767-0.919 0.747 0.587-0.896 0.425
NSC Forward Sex A 0.988 0.988-0.988 0.987 0.987-0.987 0.978 0.977-0.988 0.978 0.977-0.987 0.978
B 0.982 0.977-0.988 0.981 0.977-0.987 0.988 0.988-0.988 0.987 0.987-0.987 0.988
Cyto Risk A 0.931 0.872-0.953 0.840 0.656-0.899 0.927 0.86-0.977 0.828 0.649-0.962 0.927
B 0.884 0.826-0.919 0.843 0.676-0.923 0.888 0.872-0.892 0.885 0.815-0.912 0.888
Reverse
Sex A 0.977 0.977-0.977 0.974 0.974-0.974 0.988 0.988-0.988 0.987 0.987-0.987 0.977
B 0.523 0.442-0.558 0.502 0.472-0.553 0.508 0.442-0.558 0.486 0.438-0.539 0.516
Cyto Risk A 0.906 0.837-0.965 0.788 0.635-0.947 0.924 0.895-0.953 0.893 0.839-0.968 0.907
B 0.663 0.198-0.919 0.704 0.5-0.854 0.819 0.814-0.837 0.520 0.5-0.579 0.653
SVM Forward Sex A 0.984 0.977-0.988 0.983 0.977-0.987 0.713 0.453-0.988 0.737 0.5-0.987 0.641
B 0.981 0.93-0.988 0.981 0.934-0.987 0.817 0.488-0.988 0.799 0.45-0.987 0.782
Cyto Risk A 0.925 0.86-0.965 0.849 0.736-0.93 0.909 0.837-0.988 0.787 0.611-0.993 0.910
B 0.950 0.831-0.977 0.916 0.66-0.986 0.935 0.849-0.977 0.924 0.704-0.986 0.935
Reverse Sex A 0.603 0.547-0.698 0.563 0.5-0.667 0.986 0.977-0.988 0.985 0.974-0.987 0.587
B 0.510 0.453-0.547 0.500 0.458-0.549 0.500 0.407-0.599 0.499 0.401-0.6 0.505
Cyto Risk A 0.897 0.826-0.977 0.777 0.562-0.979 0.961 0.924-0.988 0.945 0.837-0.993 0.896
B 0.789 0.535-0.814 0.487 0.339-0.5 0.874 0.767-0942 0.798 0.61-0.94 0.793
AUC: Area under ROC curve; CI: Confidence interval; 95% CI was calculated from the bootstrap estimation.
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urement. In addition, neither k-NN nor NSC models
developed from microarray data were detrimentally af-
fected by the cross-platform gene mapping ambiguity in
predicting RNA-Seq-profiled samples. However, both k-
NN and NSC models developed from RNA-Seq data using
mapping group B were unfavorably affected by the cross-
platform gene mapping ambiguity.
The choice of modeling algorithms was also found to
affect the goodness of model level transferability. Be-
cause the SVM algorithm is much more sensitive than
k-NN and NSC to data values, SVM models developed
from one platform in predicting samples profiled with
the other platform suffered large degradation of accuracy
compared to those in predicting samples profiled with
the same platform. Relatively, the models developed using
k-NN and NSC algorithms were much more robust than
SVM.Because of the systematic differences between micro-
array and RNA-Seq gene expression measurements,
proper data transformation is essential to develop a pre-
dictive model for the cross-platform prediction. Our ana-
lysis demonstrated that per sample z-score transformation
is such an adequate approach, and furthermore has no
leakage of information from validation samples to training
process.
Microarray annotations are subject to constant updating
with changes from RefSeq, GenBank, and Ensembl data-
bases. RNA-Seq gene models also vary with improving
knowledge about the genome and functional elements
[29]. Such changes increase the complexity of cross-
platform gene mappings. Previous studies suggest that the
changes of array annotations can induce variability in
comparisons of different microarray technologies [23,30].
The current study found that array annotations and RNA-
Seq gene models can cause variation too when comparing
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The finding might provide a partial explanation as to why
the overlap of differentially expressed genes from microar-
rays and RNA-Seq is quite low [20].
We learned from the FDA-led second phase of Micro-
Array Quality Control (MAQC-II) study that the prediction
performance of microarray gene expression profile-based
models is mainly dependent on endpoints [28]. The
results of this study indicate that the transferability of
predictive models and associated signature genes be-
tween microarray and RNA-Seq data also depend on the
complexity of clinical endpoints. For example, endpoints
C_SEX_All (sex of patients) and D_FAV_All (unfavor-
able and favorable patients for extreme disease course)
of the SEQC NB data set and SEX and Cyto genetic risk
of the TCGA AML Data set were the easiest to predict
and showed the highest transferability; while E_EFS_HR
(event-free survival for high-risk patients) and F_OS_HR
(overall survival for high-risk patients) of the SEQC NB
data set and EFS and OS of the TCGA AML data set were
the most difficult to predict and exhibited the lowest
transferability. Even though the complexity of cross-
platform gene mappings can cause large variation in ab-
solute gene-expression values between microarrays and
RNA-Seq, it had minimal effect on the observed trans-
ferability of signature genes. In addition, the prediction
performance of models developed using three distinct
gene mappings was very similar to each other, indicating
that there was a lot of redundant information in both
microarray and RNA-Seq data and that only a fraction
of all the available data is necessary to derive models
with good cross-platform predictions.
Conclusions
The analyses demonstrated that microarray models can
directly predict RNA-Seq-profiled samples if the gene-
expression data were z-score preprocessed before model-
ing and prediction and that the signature genes of a model
developed from one platform can be directly transferred
to the other platform for model development. However, it
is difficult to directly use the models developed from
RNA-Seq data to predict microarray-profiled samples.
Our study offers a viable option for the proper use of leg-
acy microarray data, microarray-based predictive models
and biomarkers in the RNA-Seq era and demonstrated a
means to utilize RNA-Seq-based signature genes in micro-
array data analysis.
Methods and materials
Neuroblastoma (NB) data set from the FDA SEquencing
Quality Control (SEQC) project
The FDA SEQC NB data set contains 498 NB samples
that were independently profiled with Agilent customized
4 ? 44 K oligonucleotide microarrays and Illumina HiSeq2000 RNA-Seq. In the FDA SEQC NB study, six binary
clinically relevant endpoints and four continuous survival
times were defined among the 498 NB samples (Table 1).
For each clinical endpoint, samples were assigned to either
a training set or a validation set, with varying numbers of
positive and negative samples in each set (Table 1). De-
tailed information on the NB samples, clinical parameters,
microarrays and RNA-Seq assays were described else-
where. The data set can be obtained from GEO database
with series accession numbers GSE49710 and GSE62564
for microarray and RNA-Seq data, respectively.
Acute myeloid leukemia (AML) data from The Cancer
Genome Atlas (TCGA)
The TCGA AML [17] data set includes 175 paired Affy-
metrix HG-U133_plus_2 microarrays and Illumina RNA-
Seq assays after cleaning up the cytogenetic risk endpoint.
The microarray and RNA-Seq data were generated from
the same set of AML tumor RNA samples. The micro-
array MAS5 normalized data and RNA-Seq RPKM data
were downloaded from [31,32], respectively. The clinical
information of patients was downloaded from [31].
We used patients ? sex and cytogenetic risk as two bin-
ary endpoints for binary endpoint prediction analysis
and used event-free survival (EFS) and overall survival
(OS) times as two continuous responses with Cox pro-
portional hazards regression to predict patients ? poten-
tial survival risk based on gene expression data. The
training and validation sets were constructed as follow:
(1) since the original cytogenetic risk includes good,
intermediate, and poor three levels, we combined the
intermediate and poor levels together to form a new
? poor ? level and used with the original good level for bin-
ary endpoint prediction analysis; (2) Then randomly split
the patients in the two cytogenetic risk groups into a
training set (17 good +51 intermediate +21 poor) and a
validation set (16 good +50 intermediate +20 poor). The
same splitting was also used for the endpoint sex. The
training set includes 43 female and 46 male patients,
while the validation set contains 39 female and 47 male
patients.
NCTR rat toxicogenomics data set
The NCTR rat toxicogenomics data set includes eight
microarray and eight RNA-Seq assays. The microarray
and RNA-Seq data were generated from exactly the
same set of RNA samples isolated from the kidneys of
four aristolochic acid-treated and four control rats [20].
The microarray assays were done in the MicroArray
Quality Control phase I (MAQC-I) validation study [21]
with Affymetrix Rat_230_2 arrays and the RNA-Seq data
were generated in another study [20] with the Illumina
GA II platform and single-end 36 base pairs length
protocol. The microarray data were previously processed
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against UCSC Rat genome rn4 [33] using Novoalign
v2.08.1 [34] and gene counts were quantified and nor-
malized with the P2 pipeline [22]. The microarray and
RNA-Seq data can be downloaded from GEO database
with series accession numbers GSE5350 and GSE21210,
respectively.
FDA SEquencing Quality Control (SEQC) main study data
and MicroArray Quality Control phase I (MAQC-I) main
study data
Microarray data came from the FDA MAQC main study
[23] and consisted of data from Affymetrix HG-
U133_Plus_2 microarrays. The RNA-Seq data were
from the FDA SEQC main study [16] using the Illumina
HiSeq 2000 platform. The microarray data were generated
by Affymetrix site 1 in the MAQC study, while the RNA-
Seq data were generated by site BGI in the SEQC study.
Both sets of data were generated from the same set of four
human RNA samples, that is, Universal Human Reference
RNA (UHRR, Agilent), Human Brain Reference RNA
(HBRR, Life Technologies), and mixtures C and D of
UHRR and HBRR samples in a ratio of 3:1 and 1:3, re-
spectively. The HG-U133_Plus_2 arrays were normalized
with MAS5 algorithm. The RNA-Seq data were generated
with Illumina HiSeq 2000 using the paired-end 100 bp
TruSeq v3 RNA-Seq protocol and were analyzed with the
P2 pipeline [22] using UCSC human genome hg19 as ref-
erence. Gene counts were normalized into reads per mil-
lion (RPM) with a global scaling approach [35]. The
microarray and RNA-Seq data can be obtained from GEO
database with series accession numbers GSE5350 and
GSE47774, respectively.
FDA SEQC rat toxicogenomics data
The SEQC rat toxicogenomics data contains 62 rat liver
RNA samples. Each individual RNA sample was separ-
ately assayed with Affymetrix Rat_230_2 arrays and Illu-
mina HiScanSQ/HiSeq 2000 RNA-Seq. The microarray
data were generated and normalized in the National
Toxicology Program DrugMatrix Database. Details about
the data generation and normalization can be found
elsewhere [22]. Here, we directly downloaded MAS5
normalized data from the DrugMatrix ftp site [36]. For
RNA-Seq analysis, the paired-end 100 base pair Illumina
TruSeq RNA-Seq protocol was used. The RNA-Seq reads
were analyzed with six different bioinformatics pipelines
with different references used by six independent data
analysis teams (Table 4), that is, P1 (NCBI magic), P2
(Novoalign with RefSeq gene models), P3 (Bwa + RefSeq
RNAs), P4 (Tophat + HTSeq with RefSeq gene models),
P5 (Bowtie + RSEM with Ensembl gene models), and
P6 (Tophat + cufflinks de novo assembly). Details
about RNA-Seq reads generation, alignment, and genecounting can be found elsewhere [22]. The microarray
and RNA-Seq data can be downloaded from GEO
database with series accession number GSE47875 and
GSE55347, respectively.Cross-platform gene mapping between microarray and
RNA-Seq
The method used for cross-platform gene mapping be-
tween microarray probes/probe sets and RNA-Seq genes
is depicted in Figure 3a. The workflow was implemented
in a software tool that can be obtained upon request. Two
mapping methods, public gene ID mapping and genome
location mapping, were implemented in the software tool.
To use both approaches, the array probes/probe sets
annotation information for individual microarray is re-
quired. For Affymetrix arrays, annotation files, usually
in CSV format, are available at the Affymetrix web site
[37]. Information for RNA-Seq genes can be in one of two
formats: (1) a gene ID list file containing one of the fol-
lowing public gene IDs: RefSeq transcript ID, gene symbol,
Ensembl gene ID, or Entrez gene ID; or (2) a GTF/GFF file
generated by RNA-Seq pipelines during de novo assembly
or used by RNA-Seq pipelines for quantification of gene
expression.
To map by one of the four types of public gene IDs,
each array probe/probe set was examined by comparing
the gene ID or ID list in the corresponding array type
annotation file to all RNA-Seq genes. In order to map
with a genome location mapping approach, the coordi-
nates in the ?Alignments? column of array type annotation
files were used to calculate the overlap between each
microarray probe set and all exons of each RNA-Seq gene.
A microarray probe set was considered to be mapped to a
RNA-Seq gene if the length of the overlap between the co-
ordinates specified in the annotation file and an exon of
an RNA-Seq gene was greater than 40 base pairs, or if it
overlapped with at least two exons of the RNA-Seq gene.
After mapping, both microarray probes/probe sets and
RNA-Seq genes were separately classified into four differ-
ent groups: A, B, C, and D (Table 2).Microarray gene annotation files
The Agilent customized 4 ? 44 K oligonucleotide micro-
array annotation file was obtained from the GEO database
with series accession number GSE49710.
The microarray probe set annotation files for Rat230_2
and HG-U133_Plus_2 were downloaded from the Affymetrix
web site [37]. Both files were created on 9 June 2011 by using
the Netaffx? Annotation software. The HG-U133_Plus_2
and Rat230_2 array types were annotated with human
genome UCSC version hg19 (or NCBI GRCh37) and rat
genome UCSC version rn4, respectively. Other refer-
ence databases used for both array types for annotation
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RefSeq release 41.T-index for assessing model transferability
We used the T-index [24] score to measure the transferabil-
ity of predictive models and signature genes. The T-index
score has a value between 0 and 1. A larger T-index score
means better transferability across platforms and a T-index
score less than 0.5 indicates that the transferability is due





















where TA is a metric for estimating the transferability
of the models developed from platform A to the models
for platform B. N is the total number of models (500 in
this study). PAk and P
B
k are prediction accuracies of the
models developed from platform A and B, respectively.
s.d. is the standard deviation of (PAk −P
B
k ).RNA-Seq pipelines and gene models
Table 4 lists the RNA-Seq pipelines and gene models
used for each RNA-Seq data set used in the study.Data availability
The SEQC NB microarray gene expression data and
RNA-Seq log2RPM used in this study can be downloaded
from the GEO database with series accession number
GSE49710 and GSE62564, respectively. The TCGA AML
clinical information, microarray and RNA-Seq data can be





gaf2.0_rpkm_matrix.txt.tcgaID.txt.gz. The NCTR rat toxi-
cogenomics microarray and RNA-Seq data can be ob-
tained with GEO series accession numbers GSE5350 and
GSE21210, respectively. The MAQC-I main study and the
SEQC main study data can be downloaded from GEO
database with series accession numbers GSE5350 and
GSE47774, respectively. The SEQC rat toxicogenomics
microarray and RNA-Seq data have been deposited in
GEO database under series accession numbers GSE47875
and GSE55347, respectively.Additional files
Additional file 1: Figure S1. Comparison of the number of samples
profiled by expression microarray and RNA-Seq in the Gene Expression
Omnibus (GEO) database. The numbers of samples for expression profiling
by microarray or by high throughput sequencing (RNA-Seq) were collected
from the GEO database on 28 April 2014. In the GEO database, the start
dates for expression microarray and RNA-Seq data accumulation are 2001
and 2006, respectively. Each bar (blue or red) represents the number of
samples for expression profiling cumulated in the GEO database since the
start date (2001 and 2006 for microarray and RNA-Seq, respectively). The
dashed blue and red lines are the trend lines fitted with the ?Polynomial? and
?Power? options, respectively, in Excel. The bars after 2013 are the projections
of the trend lines fitted with current the GEO data.
Additional file 2: Figure S2. The consistency of Affymetrix microarray
and RNA-Seq gene expression levels for MAQC reference RNA samples.
The intensities of Affymetrix microarray probe sets in three mapping
groups A, B, and C are separately compared to the corresponding RNA-Seq
gene counts in panels (a), (b), and (c) for one of the four MicroArray Quality
Control (MAQC) human RNA samples. The mappings from microarray probe
sets to RNA-Seq genes are based on the genome location mapping approach.
The microarray data are from MAQC-I Affymetrix HG-U133_Plus_2 arrays with
MAS5-normalized probe set intensities, and the RNA-Seq reads are from the
FDA SEquencing Quality Control (SEQC) Illumina HiSeq 2000 with gene counts
from the P2 pipeline (Novoalign with RefSeq human gene models).
Additional file 3: Figure S3. The consistency of Affymetrix HG-
U133_Plus_2 microarray and RNA-Seq gene expression levels for the acute
myeloid leukemia (AML) RNA samples. The intensities of Affymetrix array probe
sets in three mapping groups A, B, and C are separately compared to the
corresponding RNA-Seq gene counts in panels (a), (b), and (c) for one of the
175 acute myeloid leukemia (AML) RNA samples from The Cancer Genome
Atlas (TCGA) acute myeloid leukemia study. The microarray data are MAS5
normalized and the RNA-Seq data are scaled as RPKM. The mappings from array
probe sets to RNA-Seq genes are based on the gene ID mapping approach.
Additional file 4: Figure S4. The consistency of Agilent microarray and
RNA-Seq gene expression levels for human RNA samples. The intensities
of Agilent array probes in three mapping groups A, B, and C are separately
compared to the corresponding RNA-Seq gene counts in panels (a), (b),
and (c) for one of the 498 neuroblastoma RNA samples from the FDA
SEquencing Quality Control (SEQC) project. The mappings from Agilent
probes to RNA-Seq genes are based on the gene ID mapping approach.
The microarray data are from Agilent customized 4 ? 44 K oligonucleotide
arrays, and RNA-Seq reads are from Illumina HiSeq 2000 with gene counts
from the P2 pipeline (Novoalign with RefSeq human gene models).
Additional file 5: Figure S5. The consistency of microarray gene
expression levels and six sets of RNA-Seq gene counts derived from the
same set of RNA-Seq raw data but using a diversity of RNA-Seq data
analysis approaches. The MAS5 normalized microarray gene expression
levels of mapping groups A, B, and C are plotted against the corresponding
RNA-Seq measurements generated by six independent data analysis
teams with a variety of bioinformatics pipelines and references, that
is, (a) P1 (NCBI Magic), (b) P2 (Novoalign with RefSeq rat gene models),
(c) P3 (BWA+RefSeq Rat RNAs), (d) P4 (Tophat +HTSeq with RefSeq rat gene
models), (e) P5 (Bowtie + RSEM with Ensembl rat gene models), and (f) P6
(Tophat + Cufflinks de novo assembly). The mappings from microarrays to P1, P2,
P3, and P4 gene sets are based on the gene ID mapping approach, while to P5
and P6 gene sets on the genome location mapping. The data set containing 62
rat liver RNAs is from sample profiling in the FDA SEquencing Quality Control
toxicogenomics study with separate assays for each individual RNA sample
from Affymetrix Rat_230_2 arrays and Illumina HiScanSQ/HiSeq 2000
RNA-Seq. In each of the six subpanels, gene expression measurements
for mapping groups A, B, and C from microarrays are plotted against
those from RNA-Seq in scatter plots (1), (2), and (3), respectively.
Additional file 6: Figure S6. A performance comparison of nearest
shrunken centroids (NSC) models and their corresponding transferred
models based on the SEQC NB data. For each of the six binary clinical
endpoints and each of the three mapping groups A, B, and C, a set of
500 NSC models were developed from microarray training data and used
to predict microarray validation samples. The signature genes of each of
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for those genes to build an untrained RNA-Seq model to predict RNA-Seq
validation samples. Finally, the average prediction accuracies of the 500
microarray models are plotted against those of the 500 corresponding
RNA-Seq models (a), with the per sample agreement better than chance
evaluated with the Kappa statistic as shown in (b). The transferability of
the signature genes from RNA-Seq back to microarray data was conversely
calculated. The 500 NSC models trained from RNA-Seq data were used
to predict RNA-Seq validation samples. Then the signature genes of
each RNA-Seq model were used with all microarray training data for
those genes to build an untrained NSC model to predict microarray
validation samples. The average accuracies of the 500 RNA-Seq models
were then compared to those of the 500 corresponding microarray
models (c), with the per sample agreement better than chance assessed
with the Kappa statistic as shown in (d). The six symbols in each
panel represent the six binary clinical endpoints with green, blue,
and orange colors denoting mapping groups A, B, and C, respectively.
In panels (b) and (d), each symbol denotes the average Kappa statistic
of the 500 pairs of model predictions; and each error bar shows the
95% confidence interval (CI) for the mean Kappa statistic. Each CI
was calculated with the bootstrap estimation. No significant difference
is observed between trained microarrays models and transferred
RNA-Seq models (paired t-test P is 0.841) and between the trained
RNA-Seq models and the transferred microarray models (paired t-test
P is 0.058).
Additional file 7: Figure S7. A performance comparison of support
vector machine (SVM) models and their corresponding transferred
models based on the SEQC NB data. For each of the six binary clinical
endpoints and each of the three mapping groups A, B, and C, a set of
500 SVM models were developed from microarray training data and used
to predict microarray validation samples. The signature genes of each of
the 500 models were then used with all RNA-Seq training data for those
genes to build a RNA-Seq model to predict RNA-Seq validation samples.
Finally, the average prediction accuracies of the 500 microarray models
are plotted against those of the 500 corresponding RNA-Seq models (a),
with the per sample agreement better than chance evaluated with the
Kappa statistic as shown in (b). The transferability of the signature genes
from RNA-Seq back to microarray data was conversely computed. The
500 SVM models trained from RNA-Seq data were used to predict
RNA-Seq validation samples. Then the signature genes of each RNA-Seq
model were used with all microarray training data for those genes to
build a microarray model to predict microarray validation samples. The
average accuracies of the 500 RNA-Seq models were then compared to
those of the 500 corresponding microarray models (c), with the per
sample agreement better than chance assessed with the Kappa statistic
as shown in (d). The six symbols in each panel represent the six binary
clinical endpoints with green, blue, and orange colors denoting mapping
groups A, B, and C, respectively. In panels (b) and (d), each symbol
denotes the average Kappa statistic of the 500 pairs of models; and each
error bar shows the 95% confidence interval (CI) for the mean Kappa statistic.
Each CI was calculated with the bootstrap estimation. No significant
difference is observed between trained microarray models and transferred
untrained RNA-Seq models (paired t-test P is 0.557) and between
trained RNA-Seq models and transferred untrained microarray models
(paired t-test P is 0.158).
Additional file 8: Table S1. Performance metrics for the assessment of
cross-platform transferability of signature genes of NSC models based on
the SEQC NB data.
Additional file 9: Table S2. Performance metrics for the assessment of
cross-platform transferability of signature genes of SVM models based on
the SEQC NB data.
Additional file 10: Figure S8. A performance comparison of nearest
shrunken centroids (NSC) models in predicting microarray and RNA-Seq
validation data based on the SEQC NB data. In the comparison, both
microarray log2 intensity and RNA-Seq log2 count were per sample
z-scored. For each of the six binary clinical endpoints and each of the
two mapping groups A and B, a set of 500 NSC models were developed
from microarray and RNA-Seq training data independently. Each set of NCS
models were then used to predict both microarray and RNA-Seq validationsamples. The average prediction accuracies of the 500 microarray-based
models in prediction microarray data were plotted against those in predicting
RNA-Seq data (a), with per sample agreement better than chance assessed
with the Kappa statistic as shown in (b); while the average accuracies of the
500 RNA-Seq-based models in predicting RNA-Seq data were compared to
those in predicting microarray data (c), with per sample agreement better
than chance evaluated with the Kappa statistic as shown in (d). The six symbols
in each panel represent the six binary clinical endpoints with green and blue
colors denoting mapping groups A and B, respectively. In panels (b) and (d),
each symbol denotes the average Kappa statistic of 500 pairs of prediction
results; and each error bar shows the 95% confidence interval (CI) for the mean
Kappa statistic. Each CI was calculated with the bootstrap estimation.
Additional file 11: Table S3. The performance of NSC models in
predicting microarray and RNA-Seq validation samples based on the
SEQC NB data.
Additional file 12: Figure S9. A performance comparison of support
vector machine (SVM) models in predicting microarray and RNA-Seq validation
data based on the SEQC NB data. In the comparison, both microarray log2
intensity and RNA-Seq log2 count were per sample z-score transformed. For
each of the six binary clinical endpoints and each of the two mapping groups
A and B, a set of 500 SVM models were developed from microarray and RNA-
Seq training data independently. Each set of models were then used to
predict both microarray and RNA-Seq validation samples. The average
prediction accuracies of the 500 microarray-based models in prediction
microarray data were plotted against those in predicting RNA-Seq data
(a), with per sample agreement better than chance assessed with the
Kappa statistic as shown in (b); while the average accuracies of the 500
RNA-Seq-based models in predicting RNA-Seq data were compared to
those in predicting microarray data (c), with per sample agreement
evaluated with the Kappa statistic as shown in (d). The six symbols in
each panel represent the six binary clinical endpoints with green and
blue colors denoting mapping groups A and B, respectively. In panels
(b) and (d), each symbol denotes the average Kappa statistic of 500
pairs of prediction results; and each error bar shows the 95% confidence
interval (CI) for the mean Kappa statistic. Each CI was calculated with
the bootstrap estimation.
Additional file 13: Table S4. The performance of SVM models in
predicting microarray and RNA-Seq validation samples based on the
SEQC NB data.
Additional file 14: Figure S10. A performance comparison of k-nearest
neighbors (k-NN) models in predicting microarray and RNA-Seq validation
samples, based on the SEQC NB Data without per sample z-score
transformation. In the comparison, microarray and RNA-Seq data were
log2 intensity data and log2 counts, respectively. For each of the six
binary clinical endpoints and each of the two mapping groups A and
B, a set of 500 k-NN models were developed from microarray and
RNA-Seq training data independently. Each set of k-NNs models were
then used to predict both microarray and RNA-Seq validation samples.
The average prediction accuracies of the 500 microarray-based models
in prediction microarray data were plotted against those in predicting
RNA-Seq data (a), with per sample agreement better than chance
assessed with the Kappa statistic as shown in (b); while the average
accuracies of the 500 RNA-Seq-based models in predicting RNA-Seq
data were compared to those in predicting microarray data (c), with
per sample agreement better than chance evaluated with the Kappa
statistic as shown in (d). The six symbols in each panel represent the
six binary clinical endpoints with green and blue colors denoting
mapping groups A and B, respectively. In panels (b) and (d), each symbol
denotes the average Kappa statistic of 500 pairs of prediction results; and
each error bar shows the 95% confidence interval (CI) for the mean Kappa
statistic. Each CI was calculated with the bootstrap estimation.
Additional file 15: Figure S11. A performance comparison of nearest
shrunken centroids (NSC) models in predicting microarray and RNA-Seq
validation samples, based on the SEQC NB Data without per sample
z-score transformation. In the comparison, microarray and RNA-Seq data
were log2 intensity data and log2 counts, respectively. For each of the six
binary clinical endpoints and each of the two mapping groups A and B,
a set of 500 NSC models were developed from microarray and RNA-Seq
training data independently. Each set of NCS models were then used to
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prediction accuracies of the 500 microarray-based models in prediction
microarray data were plotted against those in predicting RNA-Seq data
(a), with per sample agreement better than chance assessed with the
Kappa statistic as shown in (b); while the average accuracies of the 500 RNA-
Seq-based models in predicting RNA-Seq data were compared to those in
predicting microarray data (c), with per sample agreement better than
chance evaluated with the Kappa statistic as shown in (d). The six symbols in
each panel represent the six binary clinical endpoints with green and blue
colors denoting mapping groups A and B, respectively. In panels (b) and (d),
each symbol denotes the average Kappa statistic of 500 pairs of prediction
results; and each error bar shows the 95% confidence interval (CI) for the
mean Kappa statistic. Each CI was calculated with the bootstrap estimation.
Additional file 16: Figure S12. A performance comparison of support
vector machine (SVM) models in predicting microarray and RNA-Seq
validation samples, based on the SEQC NB Data without per sample
z-score transformation. In the comparison, microarray and RNA-Seq data
were log2 intensity data and log2 counts, respectively. For each of the six
binary clinical endpoints and each of the two mapping groups A and B,
a set of 500 SVM models were developed from microarray and RNA-Seq
training data independently. Each set of models were then used to predict
both microarray and RNA-Seq validation samples. The average prediction
accuracies of the 500 microarray-based models in prediction microarray data
were plotted against those in predicting RNA-Seq data (a), with per sample
agreement better than chance assessed with the Kappa statistic as shown
in (b); while the average accuracies of the 500 RNA-Seq-based models in
predicting RNA-Seq data were compared to those in predicting microarray
data (c), with per sample agreement better than chance evaluated with the
Kappa statistic as shown in (d). The six symbols in each panel represent the
six binary clinical endpoints with green and blue colors denoting mapping
groups A and B, respectively. In panels (b) and (d), each symbol denotes the
average Kappa statistic of 500 pairs of prediction results; and each error bar
shows the 95% confidence interval (CI) for the mean Kappa statistic. Each CI
was calculated with the bootstrap estimation.
Additional file 17: Table S5. Concordance indices and P values for the
assessment of cross-platform transferability of signature genes of Cox
models based on the SEQC NB data.
Additional file 18: Table S6. The performance of Cox proportional
hazards models developed from one-platform in predicting microarray
and RNA-Seq validation samples based on the SEQC NB data.
Additional file 19: Figure S13. A performance comparison of nearest
shrunken centroids (NSC) models and their corresponding transferred
models based on the TCGA AML data. For each of the two binary clinical
endpoints and each of the three mapping groups A, B, and C, a set of
500 NSC models were developed from microarray training data and used
to predict microarray validation samples. The signature genes of each of
the 500 microarray models were then used with all RNA-Seq training data
for those genes to build an untrained RNA-Seq model to predict
RNA-Seq validation samples. Finally, the average prediction accuracies of the
500 microarray models are plotted against those of the 500 corresponding
RNA-Seq models (a), with the per sample agreement better than chance
evaluated with the Kappa statistic as shown in (b). The transferability of the
signature genes from RNA-Seq back to microarray data was conversely
calculated. The 500 NSC models trained from RNA-Seq data were used to
predict RNA-Seq validation samples. Then the signature genes of each
RNA-Seq model were used with all microarray training data for those genes
to build an untrained NSC model to predict microarray validation samples.
The average accuracies of the 500 RNA-Seq models were then compared to
those of the 500 corresponding microarray models (c), with the per sample
agreement better than chance assessed with the Kappa statistic as shown
in (d). The two symbols in each panel represent the two binary clinical
endpoints with green, blue, and orange colors denoting mapping groups A,
B, and C, respectively. In panels (b) and (d), each symbol denotes the average
Kappa statistic of the 500 pairs of model predictions; and each error bar
shows the 95% confidence interval (CI) for the mean Kappa statistic. Each CI
was calculated with the bootstrap estimation. No significant difference is
observed between trained microarrays models and transferred RNA-Seq
models (paired t-test P is 0.354) and between the trained RNA-Seq models
and the transferred microarray models (paired t-test P is 0.106).Additional file 20: Figure S14. A performance comparison of support
vector machine (SVM) models and their corresponding transferred
models based on the TCGA AML data. For each of the two binary clinical
endpoints and each of the three mapping groups A, B, and C, a set of
500 SVM models were developed from microarray training data and used
to predict microarray validation samples. The signature genes of each of
the 500 models were then used with all RNA-Seq training data for those
genes to build a RNA-Seq model to predict RNA-Seq validation samples.
Finally, the average prediction accuracies of the 500 microarray models
are plotted against those of the 500 corresponding RNA-Seq models (a),
with the per sample agreement better than chance evaluated with the
Kappa statistic as shown in (b). The transferability of the signature genes
from RNA-Seq back to microarray data was conversely computed. The
500 SVM models trained from RNA-Seq data were used to predict
RNA-Seq validation samples. Then the signature genes of each RNA-Seq
model were used with all microarray training data for those genes to
build a microarray model to predict microarray validation samples. The
average accuracies of the 500 RNA-Seq models were then compared to
those of the 500 corresponding microarray models (c), with the per
sample agreement better than chance assessed with the Kappa statistic
as shown in (d). The two symbols in each panel represent the two binary
clinical endpoints with green, blue, and orange colors denoting mapping
groups A, B, and C, respectively. In panels (b) and (d), each symbol
denotes the average Kappa statistic of the 500 pairs of models; and each
error bar shows the 95% confidence interval (CI) for the mean Kappa statistic.
Each CI was calculated with the bootstrap estimation. No significant difference
is observed between trained microarray models and transferred untrained
RNA-Seq models (paired t-test P is 0.305) and between trained RNA-Seq
models and transferred untrained microarray models (paired t-test
P is 0.022).
Additional file 21: Table S7. Concordance indices and p values for the
assessment of cross-platform transferability of signature genes of Cox
models based on the TCGA AML data.
Additional file 22: Figure S15. A performance comparison of nearest
shrunken centroids (NSC) models in predicting microarray and RNA-Seq
validation data based on the TCGA AML data. In the comparison, both
microarray log2 intensity and RNA-Seq log2 count were per sample
z-scored. For each of the two clinical binary endpoints and each of the
two mapping groups A and B, a set of 500 NSC models were developed
from microarray and RNA-Seq training data independently. Each set of
NCS models were then used to predict both microarray and RNA-Seq
validation samples. The average prediction accuracies of the 500
microarray-based models in prediction microarray data were plotted
against those in predicting RNA-Seq data (a), with per sample agreement
better than chance assessed with the Kappa statistic as shown in (b); while
the average accuracies of the 500 RNA-Seq-based models in predicting
RNA-Seq data were compared to those in predicting microarray data
(c), with per sample agreement better than chance evaluated with the
Kappa statistic as shown in (d). The two symbols in each panel represent the
two binary clinical endpoints with green and blue colors denoting mapping
groups A and B, respectively. In panels (b) and (d), each symbol denotes the
average Kappa statistic of 500 pairs of prediction results; and each error bar
shows the 95% confidence interval (CI) for the mean Kappa statistic. Each CI
was calculated with the bootstrap estimation.
Additional file 23: Figure S16. A performance comparison of support
vector machine (SVM) models in predicting microarray and RNA-Seq
validation data based on the TCGA AML data. In the comparison, both
microarray log2 intensity and RNA-Seq log2 count were per sample
z-score transformed. For each of the two binary clinical endpoints and
each of the two mapping groups A and B, a set of 500 SVM models were
developed from microarray and RNA-Seq training data independently.
Each set of models were then used to predict both microarray and
RNA-Seq validation samples. The average prediction accuracies of the 500
microarray-based models in prediction microarray data were plotted
against those in predicting RNA-Seq data (a), with per sample agreement
better than chance assessed with the Kappa statistic as shown in (b);
while the average accuracies of the 500 RNA-Seq-based models in predicting
RNA-Seq data were compared to those in predicting microarray data (c),
with per sample agreement evaluated with the Kappa statistic as shown in
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endpoints with green and blue colors denoting mapping groups A and B,
respectively. In panels (b) and (d), each symbol denotes the average Kappa
statistic of 500 pairs of prediction results; and each error bar shows the 95%
confidence interval (CI) for the mean Kappa statistic. Each CI was calculated
with the bootstrap estimation.
Additional file 24: Figure S17. A performance comparison of k-nearest
neighbors (k-NN) models in predicting microarray and RNA-Seq validation
samples, based on the TCGA AML data without per sample z-score
transformation. In the comparison, microarray and RNA-Seq data were
log2 intensity data and log2 counts, respectively. For each of the two
binary clinical endpoints and each of the two mapping groups A and
B, a set of 500 k-NN models were developed from microarray and
RNA-Seq training data independently. Each set of k-NNs models were
then used to predict both microarray and RNA-Seq validation samples.
The average prediction accuracies of the 500 microarray-based models
in prediction microarray data were plotted against those in predicting
RNA-Seq data (a), with per sample agreement better than chance
assessed with the Kappa statistic as shown in (b); while the average
accuracies of the 500 RNA-Seq-based models in predicting RNA-Seq
data were compared to those in predicting microarray data (c), with per
sample agreement better than chance evaluated with the Kappa statistic
as shown in (d). The two symbols in each panel represent the two
binary clinical endpoints with green and blue colors denoting mapping
groups A and B, respectively. In panels (b) and (d), each symbol denotes
the average Kappa statistic of 500 pairs of prediction results; and each
error bar shows the 95% confidence interval (CI) for the mean Kappa
statistic. Each CI was calculated with the bootstrap estimation.
Additional file 25: Figure S18. A performance comparison of nearest
shrunken centroids (NSC) models in predicting microarray and RNA-Seq
validation samples, based on the TCGA AML data without per sample
z-score transformation. In the comparison, microarray and RNA-Seq data
were log2 intensity data and log2 counts, respectively. For each of the
two binary clinical endpoints and each of the two mapping groups A
and B, a set of 500 NSC models were developed from microarray and
RNA-Seq training data independently. Each set of NCS models were then
used to predict both microarray and RNA-Seq validation samples. The
average prediction accuracies of the 500 microarray-based models in
prediction microarray data were plotted against those in predicting
RNA-Seq data (a), with per sample agreement better than chance assessed
with the Kappa statistic as shown in (b); while the average accuracies of the
500 RNA-Seq-based models in predicting RNA-Seq data were compared to
those in predicting microarray data (c), with per sample agreement better
than chance evaluated with the Kappa statistic as shown in (d). The two
symbols in each panel represent the two binary clinical endpoints with
green and blue colors denoting mapping groups A and B, respectively. In
panels (b) and (d), each symbol denotes the average Kappa statistic of 500
pairs of prediction results; and each error bar shows the 95% confidence
interval (CI) for the mean Kappa statistic. Each CI was calculated with the
bootstrap estimation.
Additional file 26: Figure S19. A performance comparison of support
vector machine (SVM) models in predicting microarray and RNA-Seq
validation samples, based on the TCGA AML data without per sample
z-score transformation. In the comparison, microarray and RNA-Seq data
were log2 intensity data and log2 counts, respectively. For each of the
two binary clinical endpoints and each of the two mapping groups A
and B, a set of 500 SVM models were developed from microarray and
RNA-Seq training data independently. Each set of models were then used
to predict both microarray and RNA-Seq validation samples. The average
prediction accuracies of the 500 microarray-based models in prediction
microarray data were plotted against those in predicting RNA-Seq data
(a), with per sample agreement better than chance assessed with the
Kappa statistic as shown in (b); while the average accuracies of the 500
RNA-Seq-based models in predicting RNA-Seq data were compared to
those in predicting microarray data (c), with per sample agreement better
than chance evaluated with the Kappa statistic as shown in (d). The two
symbols in each panel represent the two binary clinical endpoints with
green and blue colors denoting mapping groups A and B, respectively. In
panels (b) and (d), each symbol denotes the average Kappa statistic of500 pairs of prediction results; and each error bar shows the 95% confidence
interval (CI) for the mean Kappa statistic. Each CI was calculated with the
bootstrap estimation.
Additional file 27: Table S8. The performance of Cox proportional
hazards models developed from one-platform in predicting microarray
and RNA-Seq validation samples based on the TCGA AML data.
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